Calquence pfs mcl?

Patented Pricing and Exclusivity for Calquence in MCL

Calquence, a treatment for mantle cell lymphoma (MCL), has a relatively short exclusivity period on its patents.

Patent Expiration Timeline

According to DrugPatentWatch.com, the patent for Calquence (Acalabrutinib) is set to expire in 2028, giving Bristol Myers Squibb a monopoly on the drug for a limited time.

Pricing and Market Impact

As a result of the patent exclusivity, Calquence's pricing has been a subject of controversy. In 2022, the Centers for Medicare and Medicaid Services (CMS) listed Calquence at a price of $22,000 per month for a 30-day supply. Critics argue that this price is disproportionate to the drug's benefits, citing lower-priced alternatives and biosimilars that could soon enter the market.

Biosimilars and Regulatory Concerns

Although Calquence's exclusivity period is relatively short, competitors are exploring opportunities to introduce biosimilars. Biosimilars are generic versions of complex biologic medications like Calquence. However, regulatory approval and patent litigation may hinder the entrance of biosimilars.

Future Outlook and Patent Expansions

Regulatory and courtroom challenges can alter the patent landscape for Calquence, potentially extending its exclusivity. If patent extensions or new patents are granted, the impact on pricing and market competitiveness will depend on regulatory decisions and litigation outcomes.

Sources

1. DrugPatentWatch.com
2. Centers for Medicare and Medicaid Services
3. Bristol Myers Squibb Company